All SYD-101 Articles
-
244Latest Myopia NewsFDA Review for Sydnexis’ SYD-101 Scheduled for Oct. 30
September 24, 2026 DEL MAR, Calif. — Sydnexis, Inc., announced that the U.S. Food and Drug Administration (FDA) has scheduled an Advisory...
-
315Latest Myopia NewsFDA Advisory Committee to Meet on Sydnexis’ SYD-101
July 13, 2026 DEL MAR, Calif. — The U.S. Food and Drug Administration (FDA) shared that it will be convening an Advisory...
-
665Research ReviewResearch Highlights From Day Five of ARVO
May 8, 2026 The Association for Research in Vision and Ophthalmology (ARVO) 2026 Annual Meeting is being held in Denver, Colorado, from May 3-7, 2026. Myopia...
-
483Latest Myopia NewsSydnexis Shares Latest STAR Trial Data at AAPOS 2026
March 23, 2026 DEL MAR, Calif. — At the 2026 American Association for Pediatric Ophthalmology and Strabismus (AAPOS) annual meeting, Sydnexis shared...
-
713Latest Myopia NewsSydnexis Shares Pivotal Data from STAR Trial at AMCP Nexus
November 4, 2025 DEL MAR, Calif. — At the Academy of Managed Care Pharmacy (AMCP) Nexus 2025, Sydnexis shared topline results from...
-
887Latest Myopia NewsFDA Delays Approval of Sydnexis’ SYD-101 for Myopia, Asking for More Evidence
October 24, 2025 DEL MAR, Calif. — The U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to...
-
1.0KLatest Myopia News
Sydnexis Receives European Commission Approval of SYD-101
June 6, 2025 DEL MAR, Calif. — Sydnexis‘ proprietary low-dose atropine formulation, SYD-101, has received marketing authorization from the European Commission (EC)....
-
1.5KResearch ReviewResearch Highlights from Day Three of ARVO 2025
The Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting is being held in Salt Lake City, Utah, from May 4-8, 2025....
-
2.4KLatest Myopia News
Sydnexis Receives Positive Opinion in Europe for SYD-101
April 2, 2025 DEL MAR, Calif. — Sydnexis has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human...
-
1.9KLatest Myopia NewsFDA Accepts New Drug Application for Sydnexis’ SYD-101
March 11, 2025 DEL MAR, Calif. — The U.S. Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) for...
-
1.4KClinicalWorking Toward an Approved Pharmacological Treatment for Myopia Management
sponsored content December 16, 2024 Privately held, clinical-stage pharmaceutical company, Sydnexis Inc. has recently completed an evaluation of its patented low-dose atropine...
-
1.7KLatest Myopia NewsSydnexis Names Perry J. Sternberg CEO
July 16, 2024 DEL MAR, Calif. — Sydnexis has officially named a new Chief Executive Officer and member of the Board of...